Unbiased discovery of antibody therapies that stimulate macrophage-mediated destruction of B-cell lymphoma
Ribeiro, J.; Pages-Geli, C.; Meglan, A.; Velarde, J.; Blandin, J.; Vaccaro, K.; Wienclaw, T.; Fernandez-Guzman, P.; Hahn, C. K.; Crespo, M.; Weiskopf, K.
Show abstract
Macrophages are critical effectors of antibody therapies for lymphoma, but the best targets for this purpose remain unknown. Here, we sought to define a comprehensive repertoire of cell surface antigens that can be targeted to stimulate macrophage-mediated destruction of B-cell lymphoma. We developed a high-throughput assay to screen hundreds of antibodies for their ability to provoke macrophages to attack B-cell lymphoma cells. Across both mouse and human systems, we identified multiple unappreciated targets of opsonization as well as putative immune checkpoints. We used this information to engineer a compendium of 156 bispecific antibodies, and we identified dozens of bispecifics that dramatically stimulate macrophage-mediated cytotoxicity of lymphoma cells. Among these, a bispecific comprising a SIRP decoy domain and a CD38-targeting arm (WTa2d1xCD38) exhibited maximal efficacy while minimizing the risk of hematologic toxicity. This bispecific stimulated robust anti-tumor responses in multiple xenograft models of aggressive B-cell lymphoma. Our approach can be directly applied to other cancers to rapidly discover bispecific antibodies that leverage anti-tumor responses by macrophages or other innate immune cells.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies 97%
- Pooled screening for CAR function identifies novel IL13Rα2-targeted CARs for treatment of glioblastoma 96%
- Precision Enhancement of CAR-NK Cells through Non-Viral Engineering and Highly Multiplexed Base Editing 95%
Similar papers in this journal
- Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting 96%
- Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity 96%
- Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor resistant HER2-positive breast cancer 95%
Similar papers in this journal
- PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma 96%
- The CCL17-CCR4 axis is critical for mutant STAT6-mediated microenvironmental remodelling and therapeutic resistance in Relapsed/Refractory Diffuse Large B Cell Lymphoma 94%
- Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment Efficacy 94%
Similar papers in this journal
- ATP citrate lyase is an essential player of the metabolic rewiring induced by PTEN loss during T-ALL development. 93%
- Neoantigen Landscape Supports Feasibility of Personalized Cancer Vaccine for Follicular Lymphoma 93%
- Charge-Altering Releasable Transporters enable specific phenotypic manipulation of resting primary natural killer cells 93%
Similar papers in this journal
- Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicity 94%
- Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking LAIR-collagen interaction 94%
- Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.